Why the study?
Cardiovascular disease is the leading cause of mortality in women, but females, particularly pregnant or postpartum individuals, remain underrepresented in cardiovascular clinical trials.
Despite rising awareness and policy initiatives, there has been no significant increase in cardiovascular trials exclusively enrolling women or focusing on pregnant and lactating populations from 2017 to 2023, underscoring a persistent gap in sex-specific evidence generation.
Answers are grounded in this paper and cite their sources.
Persistent underenrollment of women in CV trials warrants caution in clinical extrapolation; leaves open research into enrollment barriers for pregnancy populations.
Cardiovascular disease remains the leading cause of mortality among women globally, yet females, particularly those who are pregnant or postpartum, remain underrepresented in cardiovascular clinical trials. This study assessed enrollment trends of all-female participants, including pregnant and postpartum women, in cardiovascular trials registered on ClinicalTrials.gov from 2017 to 2023. Among the trials identified, there was no significant increase in studies exclusively enrolling women or those focused on pregnancy and postpartum populations. Most trials targeted obesity (58%) and hypertension (26%) in women aged 19-55 and were predominantly sponsored by universities in the United States. Interventions were largely limited to lifestyle and pharmacologic strategies. The lack of growth in inclusive trial design underscores persistent research gaps. Greater efforts are needed across policy, funding, and trial design to ensure equitable representation of all women, particularly during vulnerable physiological stages such as pregnancy and lactation, to improve evidence-based cardiovascular care.
No takes yet. Share an insight, caveat, or question.
Pine et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: